Thoracic radiation therapy and Adriamycin/cisplatin-containing chemotherapy for locally advanced non-small-cell lung cancer.

R. T. Eagan, R. E. Lee, S. Frytak, M. Scott, J. N. Ingle, E. T. Creagan, W. C. Nichols

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

One-hundred nine patients with limited-stage unresectable non-small-cell lung cancer were treated with Adriamycin--cisplatin-based combination chemotherapy and thoracic irradiation. Of this number, 73 received chemotherapy (one course) prior to irradiation and 37% (27/73) had tumor regression following chemotherapy alone. Sixty-eight percent of patients (73/107) experienced tumor regression following combined chemotherapy and irradiation. Age more than 65 years, a malignant ipsilateral pleural effusion, and no response to chemotherapy alone were all strong negative prognostic factors. Three-year survivals were as follows: all 109 patients, 14.0%; 89 patients without malignant pleural effusion, 17.0%; 71 patients with neither a malignant pleural effusion nor malignant ipsilateral supraclavicular adenopathy, 23.1%.

Original languageEnglish (US)
Pages (from-to)381-388
Number of pages8
JournalCancer clinical trials
Volume4
Issue number4
StatePublished - Dec 1 1981

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Thoracic radiation therapy and Adriamycin/cisplatin-containing chemotherapy for locally advanced non-small-cell lung cancer.'. Together they form a unique fingerprint.

  • Cite this

    Eagan, R. T., Lee, R. E., Frytak, S., Scott, M., Ingle, J. N., Creagan, E. T., & Nichols, W. C. (1981). Thoracic radiation therapy and Adriamycin/cisplatin-containing chemotherapy for locally advanced non-small-cell lung cancer. Cancer clinical trials, 4(4), 381-388.